Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 16, 2026

Stock market today: Dow, S&P 500, Nasdaq steady as Trump wavers on Kevin Hassett as next Fed chair

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq steady as Trump wavers on Kevin Hassett as next Fed chair US stocks pared gains on Friday as uncertainty over the next Fed chair weighed on markets, while strong bank earnings and ongoing geopolitical tensions capped a volatile week…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Moving Hassett to Fed would mean losing him from current role

    80% confidence
  • Small-cap earnings are just beginning to take off after two-year earnings recession

    80% confidence
  • Affordability conditions taking toll on lower and mid-range housing sectors

    80% confidence
  • Lower interest rates help small caps as 40% of Russell 2000 debt is variable

    80% confidence
  • Trump wants to keep Kevin Hassett as NEC director rather than naming him Fed Chair

    80% confidence
  • Tehran's crackdown on protesters is easing

    80% confidence
  • Small caps can outperform for over a decade when they begin outperforming

    80% confidence
  • Fed sees risks to job market and should be ready to cut rates

    80% confidence
  • ASML shares could surge 70% in bull case

    80% confidence
  • May use tariffs in pursuit of Greenland acquisition

    80% confidence
  • Investors pondering what would push 10-year yields to 4.25% or 4.05%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com